Literature DB >> 24951427

The polycomb repressive complex 2 governs life and death of peripheral T cells.

Yuxia Zhang1, Sarah Kinkel1, Jovana Maksimovic2, Esther Bandala-Sanchez1, Maria C Tanzer1, Gaetano Naselli3, Jian-Guo Zhang1, Yifan Zhan1, Andrew M Lew1, John Silke1, Alicia Oshlack2, Marnie E Blewitt1, Leonard C Harrison1.   

Abstract

Differentiation of naïve CD4(+) T cells into effector (Th1, Th2, and Th17) and induced regulatory (iTreg) T cells requires lineage-specifying transcription factors and epigenetic modifications that allow appropriate repression or activation of gene transcription. The epigenetic silencing of cytokine genes is associated with the repressive H3K27 trimethylation mark, mediated by the Ezh2 or Ezh1 methyltransferase components of the polycomb repressive complex 2 (PRC2). Here we show that silencing of the Ifng, Gata3, and Il10 loci in naïve CD4(+) T cells is dependent on Ezh2. Naïve CD4(+) T cells lacking Ezh2 were epigenetically primed for overproduction of IFN-γ in Th2 and iTreg and IL-10 in Th2 cells. In addition, deficiency of Ezh2 accelerated effector Th cell death via death receptor-mediated extrinsic and intrinsic apoptotic pathways, confirmed in vivo for Ezh2-null IFN-γ-producing CD4(+) and CD8(+) T cells responding to Listeria monocytogenes infection. These findings demonstrate the key role of PRC2/Ezh2 in differentiation and survival of peripheral T cells and reveal potential immunotherapeutic targets.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24951427     DOI: 10.1182/blood-2013-12-544106

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

Review 1.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 2.  Regulation of CD4 T-cell differentiation and inflammation by repressive histone methylation.

Authors:  Frann Antignano; Colby Zaph
Journal:  Immunol Cell Biol       Date:  2015-01-13       Impact factor: 5.126

Review 3.  Regulation of T cell differentiation and function by epigenetic modification enzymes.

Authors:  Huicheng Liu; Pingfei Li; Zhengping Wei; Cai Zhang; Minghui Xia; Qiuyang Du; Yufei Chen; Na Liu; Huabin Li; Xiang-Ping Yang
Journal:  Semin Immunopathol       Date:  2019-04-08       Impact factor: 9.623

Review 4.  Epigenetic regulation of T helper cells and intestinal pathogenicity.

Authors:  Yuya Hagihara; Yusuke Yoshimatsu; Yohei Mikami; Yoshiaki Takada; Shinta Mizuno; Takanori Kanai
Journal:  Semin Immunopathol       Date:  2019-03-19       Impact factor: 9.623

Review 5.  miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.

Authors:  Ying Zheng; Zhen Wang; Zhiguang Zhou
Journal:  Cell Mol Immunol       Date:  2017-03-20       Impact factor: 11.530

Review 6.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

Review 7.  Emerging Role for Methylation in Multiple Sclerosis: Beyond DNA.

Authors:  Lindsay M Webb; Mireia Guerau-de-Arellano
Journal:  Trends Mol Med       Date:  2017-05-04       Impact factor: 11.951

8.  The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

Authors:  Michel DuPage; Gaurav Chopra; Jason Quiros; Wendy L Rosenthal; Malika M Morar; Dan Holohan; Ruan Zhang; Laurence Turka; Alexander Marson; Jeffrey A Bluestone
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

9.  The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).

Authors:  Olga F Sarmento; Phyllis A Svingen; Yuning Xiong; Zhifu Sun; Adebowale O Bamidele; Angela J Mathison; Thomas C Smyrk; Asha A Nair; Michelle M Gonzalez; Mary R Sagstetter; Saurabh Baheti; Dermot P B McGovern; Jessica J Friton; Konstantinos A Papadakis; Goel Gautam; Ramnik J Xavier; Raul A Urrutia; William A Faubion
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

10.  Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.

Authors:  Sangeeta Goswami; Irina Apostolou; Jan Zhang; Jill Skepner; Swetha Anandhan; Xuejun Zhang; Liangwen Xiong; Patrick Trojer; Ana Aparicio; Sumit K Subudhi; James P Allison; Hao Zhao; Padmanee Sharma
Journal:  J Clin Invest       Date:  2018-07-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.